Liraglutide Flexpen


Indications and Reactions:

Role Indications Reactions
Primary
Type 2 Diabetes Mellitus 46.4%
Obesity 15.1%
Hypertension 8.0%
Product Used For Unknown Indication 5.1%
Diabetes Mellitus 4.5%
Prophylaxis 3.0%
Back Pain 2.1%
Supraventricular Tachycardia 2.0%
Chronic Obstructive Pulmonary Disease 1.8%
Osteopenia 1.6%
Dyslipidaemia 1.5%
Hypothyroidism 1.4%
Depression 1.4%
Asthma 1.2%
Anaemia 0.9%
Hypercholesterolaemia 0.9%
Venous Insufficiency 0.8%
Vitamin B12 Deficiency 0.8%
Drug Use For Unknown Indication 0.7%
Angina Pectoris 0.7%
Lipase Increased 17.3%
Cholelithiasis 9.9%
Pancreatitis 9.6%
Abdominal Pain 7.1%
Cholecystitis Acute 6.2%
Angina Unstable 4.6%
Cholecystitis 4.0%
Pancreatitis Acute 4.0%
Pneumonia 4.0%
Abdominal Pain Upper 3.7%
Diarrhoea 3.4%
Angina Pectoris 3.1%
Chest Pain 3.1%
Coronary Revascularisation 3.1%
Myocardial Infarction 3.1%
Renal Failure Acute 3.1%
Supraventricular Tachycardia 3.1%
Gastroenteritis 2.8%
Gastritis 2.5%
Nausea 2.5%
Secondary
Type 2 Diabetes Mellitus 36.4%
Obesity 32.3%
Chronic Obstructive Pulmonary Disease 4.3%
Product Used For Unknown Indication 4.2%
Supraventricular Tachycardia 4.0%
Hypertension 2.9%
Prophylaxis 2.6%
Arthralgia 2.3%
Back Pain 1.7%
Bile Duct Stone 1.7%
Diabetes Mellitus 1.7%
Constipation 0.9%
Lung Adenocarcinoma 0.9%
Hypercholesterolaemia 0.7%
Anaemia 0.6%
Bronchial Hyperreactivity 0.6%
Dyslipidaemia 0.6%
Gastritis 0.6%
Hypothyroidism 0.6%
Osteoarthritis 0.6%
Cholelithiasis 16.7%
Lipase Increased 10.1%
Abdominal Pain 8.5%
Cholecystitis Acute 8.1%
Pancreatitis 6.2%
Pancreatitis Acute 5.4%
Abdominal Pain Upper 4.3%
Panniculitis 3.9%
Pneumonia 3.9%
Cholecystitis 3.5%
Cholecystitis Chronic 3.5%
Gastroenteritis 3.5%
Hyperlipasaemia 3.5%
Supraventricular Tachycardia 3.1%
Diarrhoea 2.7%
Hepatitis 2.7%
Myocardial Infarction 2.7%
Renal Failure Acute 2.7%
Weight Decreased 2.7%
Hepatitis Acute 2.3%

Drug Data